🔗 Share this article

The prestigious award in Physiology or Medicine was awarded for transformative findings that clarify how the body's defense network attacks harmful pathogens while sparing the healthy tissues.

A trio of renowned researchers—Japan's Shimon Sakaguchi and American scientists Dr. Brunkow and Fred Ramsdell—share this accolade.

The work uncovered specialized "sentinels" within the defense system that remove rogue defense cells that could harming the body.

The discoveries are now paving the way for new therapies for autoimmune diseases and cancer.

The laureates will share a monetary award worth 11m SEK.

Decisive Findings

"The research has been decisive for comprehending how the body's defenses functions and the reason we do not all develop serious autoimmune diseases," stated the chair of the Nobel Committee.

This trio's research explain a fundamental mystery: How does the immune system protect us from countless infections while leaving our healthy cells unharmed?

The immune system uses immune cells that scan for indicators of infection, even pathogens and germs it has never encountered.

Such cells employ detectors—known as receptors—that are generated by chance in countless variations.

This gives the defense network the capacity to combat a wide array of invaders, but the unpredictability of the process unavoidably creates white blood cells that can target the host.

Security Guards of the Immune System

Researchers earlier knew that a portion of these harmful white blood cells were destroyed in the thymus—where immune cells mature.

The latest Nobel Prize recognizes the identification of T-reg cells—known as the immune system's "peacekeepers"—which travel through the body to neutralize any immune cells that attack the healthy cells.

It is known that this mechanism malfunctions in autoimmune diseases such as type-1 diabetes, MS, and rheumatoid arthritis.

The Nobel panel stated, "These findings have established a new field of investigation and spurred the creation of innovative therapies, for instance for tumors and immune disorders."

Regarding cancer, regulatory T-cells block the system from attacking the tumor, so research are aimed at lowering their numbers.

For autoimmune diseases, trials are testing boosting T-reg cells so the organism is not being harmed. A similar approach could also be useful in reducing the risks of transplanted organ failure.

Pioneering Studies

Professor Sakaguchi, of Osaka University, performed experiments on rodents that had their thymus extracted, leading to self-attack conditions.

He showed that injecting defense cells from healthy mice could stop the disease—suggesting there was a system for preventing immune cells from attacking the host.

Dr. Brunkow, affiliated with the Institute for Systems Biology in Seattle, and Dr. Ramsdell, now at a biotech firm in a California city, were studying an genetic immune disorder in mice and people that led to the identification of a genetic factor vital for the way regulatory T-cells function.

"The pioneering research has uncovered how the body's defenses is controlled by regulatory T cells, stopping it from mistakenly attacking the body's own tissues," said a leading biological science specialist.

"The work is a remarkable example of how fundamental physiological study can have far-reaching implications for human health."